全文获取类型
收费全文 | 18202篇 |
免费 | 1375篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 149篇 |
儿科学 | 684篇 |
妇产科学 | 363篇 |
基础医学 | 2688篇 |
口腔科学 | 304篇 |
临床医学 | 1840篇 |
内科学 | 4134篇 |
皮肤病学 | 243篇 |
神经病学 | 1965篇 |
特种医学 | 657篇 |
外国民族医学 | 3篇 |
外科学 | 2336篇 |
综合类 | 253篇 |
一般理论 | 7篇 |
预防医学 | 1160篇 |
眼科学 | 663篇 |
药学 | 835篇 |
中国医学 | 14篇 |
肿瘤学 | 1331篇 |
出版年
2021年 | 208篇 |
2019年 | 239篇 |
2018年 | 283篇 |
2017年 | 225篇 |
2016年 | 268篇 |
2015年 | 287篇 |
2014年 | 361篇 |
2013年 | 533篇 |
2012年 | 781篇 |
2011年 | 835篇 |
2010年 | 480篇 |
2009年 | 468篇 |
2008年 | 676篇 |
2007年 | 822篇 |
2006年 | 808篇 |
2005年 | 743篇 |
2004年 | 767篇 |
2003年 | 664篇 |
2002年 | 710篇 |
2001年 | 614篇 |
2000年 | 602篇 |
1999年 | 487篇 |
1998年 | 233篇 |
1997年 | 197篇 |
1996年 | 182篇 |
1995年 | 184篇 |
1994年 | 162篇 |
1993年 | 158篇 |
1992年 | 435篇 |
1991年 | 415篇 |
1990年 | 407篇 |
1989年 | 363篇 |
1988年 | 370篇 |
1987年 | 345篇 |
1986年 | 355篇 |
1985年 | 327篇 |
1984年 | 272篇 |
1983年 | 230篇 |
1982年 | 164篇 |
1981年 | 160篇 |
1980年 | 137篇 |
1979年 | 219篇 |
1978年 | 187篇 |
1977年 | 137篇 |
1976年 | 143篇 |
1975年 | 143篇 |
1974年 | 166篇 |
1973年 | 163篇 |
1972年 | 133篇 |
1971年 | 131篇 |
排序方式: 共有10000条查询结果,搜索用时 453 毫秒
1.
Olga A. Klein Avril Drummond Jacqueline R. Mhizha-Murira Laura Mansford Roshan dasNair 《Neuropsychological rehabilitation》2019,29(4):491-512
While previous randomised controlled trials and meta-analyses offer only limited evidence for the effectiveness of cognitive rehabilitation, qualitative studies examining patient perspectives report more positive outcomes. This meta-synthesis of qualitative studies examined patient perspectives of cognitive rehabilitation for memory, attention, and executive function problems in people with multiple sclerosis. Using set eligibility criteria, we screened electronic databases, reference lists, and academic networks for relevant papers. Seven papers (195 participants) were selected. Two independent researchers conducted quality appraisals of papers. Data analysis, guided by the thematic synthesis approach, yielded six main themes. These suggested that patients benefitted from the group environment in rehabilitation. Cognitive rehabilitation facilitated the participants’ reflection and awareness of their cognitive deficits, and was associated with increased knowledge and understanding of their illness. Increased strategy use was reported and associated with improvements in cognitive functioning and greater confidence and perseverance. Participants reported emotional and social improvements, and felt more optimistic. Overall, these changes had a positive impact on participants’ quality of life. This synthesis of qualitative studies indicates that people with multiple sclerosis who experience cognitive deficits benefit from cognitive rehabilitation programmes. This finding must, however, be viewed in light of the limitations of this meta-synthesis. The meta-synthesis was registered in the PROSPERO database under CRD42017040148. 相似文献
2.
Stephanie A. Grilo Marina Catallozzi John S. Santelli Hanying Yan Xiaoyu Song Jennifer Heitel Kristen Kaseeska Julie Gorzkowski Alexandra E. Dereix Jonathan D. Klein 《The Journal of adolescent health》2019,64(3):311-318
Purpose
The objective of the study was to define factors associated with adolescent and young adult (AYA) experiences with private time and having discussed confidentiality and the impact of these experiences on improving delivery of clinical preventive services.Methods
In 2016, a nationally representative sample of 1,918 US AYAs (13- to 26-year-olds) was surveyed. Survey questionnaire domains were based on prior research and Fishers' information-motivation-behavior skills conceptual model. Data were weighted to represent US households with AYA and analyzed to identify factors independently associated with ever experiencing private time and discussions of confidentiality with a regular health-care provider (HCP). We examined the association of these experiences on AYA attitudes about health care.Results
Fifty-five percent of female and 49% of male AYA reported ever having had private time with an HCP and 55% of female and 44% of male AYA had spoken to an HCP about confidentiality. Independent predictors of having experienced private time and confidentiality included older age, race, higher household income, gender of the provider, amount of years with the provider, and involvement in risk behaviors. AYA who had experienced private time and confidentiality discussions had more positive attitudes about their providers, were more willing and comfortable discussing sensitive topics, and thought that these discussions should happen at younger ages.Conclusions
Although confidentiality and private time are important to AYA, many are not experiencing these components of care. Providing private time and discussions of confidentiality can improve the delivery of health care for young people by enhancing positive youth attitudes about preventive care. 相似文献3.
4.
5.
Marlene L Hauck Susan M LaRue William P Petros Jean M Poulson Daohai Yu Ivan Spasojevic Amy F Pruitt Allison Klein Beth Case Donald E Thrall David Needham Mark W Dewhirst 《Clinical cancer research》2006,12(13):4004-4010
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN: Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS: Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION: LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted. 相似文献
6.
7.
8.
9.
10.
F Elferink W J van der Vijgh W W ten Bokkel Huinink J B Vermorken I Klein B Winograd M K Knobf G Simonetti H E Gall J G McVie 《British journal of cancer》1987,56(4):479-483
Pharmacokinetics of the cis-platin analog ethylenediaminemalonatoplatinum(II) (JM-410) was studied in 28 cycles of 19 patients during the phase I study of this drug. The drug was administered intravenously by short-term (10-60 min) infusion. Doses ranged from 20 to 1,200mg m-2. JM-40 was determined in plasma ultrafiltrate and urine by HPLC. Platinum (Pt) concentrations were determined in plasma, plasma ultrafiltrate, urine and red blood cells by atomic absorption spectrometry up to 5 days after administration of the drug. Ultrafilterable Pt could be determined up to 45 days after the infusion in one patient sampled over such a long period. Pharmacokinetics of JM-40 showed a linear behaviour. The final half-life of total Pt in plasma was 4.1 +/- 0.9 days. The disposition of JM-40 was similar to that of ultrafilterable Pt in respect to t1/2 alpha (10 and 13 min), t1/2 beta (44 and 57 min), volumes of distribution Vc (11 and 121) and Vss (17 and 201), systemic clearance (256 and 223 ml min-1), renal clearance (69 and 73 ml min-1) and metabolic clearance (183 and 154 ml min-1). During the first 6 h 27 +/- 9% of the administered dose was excreted as JM-40. Cumulative platinum excretion in the urine amounted to 29 +/- 13% and 60 +/- 13% over the first 6 h, 24 h and 5 days, respectively. The uptake of platinum in red blood cells was limited, comprising only 0.24 +/- 0.12% of the administered dose. Although JM-40 and carboplatin are structurally closely related, pharmocokinetics and toxicity of JM-40 were more similar to cis-platin than to carboplatin. 相似文献